Auray, Christiane

Professeure, Faculté de médecine et des sciences de la santé
FMSS Département de pédiatrie

Coordonnées

Courriel


819-346-1110, poste 14706

Diplômes

(2008) Postdoctorat (Études postdoctorales-Fellowship). Duke University.

(2007) Doctorat (Doctorat). Université de Sherbrooke.

(1998) Maîtrise avec mémoire (LL.M. - Maîtrise). Université de Sherbrooke.

(1972) Baccalauréat (B.Sc.). Université de Sherbrooke.

Expérience académique

(2018) Full Professor. Université de Sherbrooke.

Présentation

Sujets de recherche

Analyse des lipides/lipoprotéines, Asthme, Génétique et éthique, Services de santé, Techniques diagnostiques.

Disciplines de recherche

Biochimie, Chimie, Droit, Génétique, Médecine préventive et communautaire, Mesures et évaluation, Néphrologie, Obstétrique et gynécologie, Pédiatrie.

Mots-clés

Asthme, Biobanques, Biomarqueurs, Dépistage, Éthique, Maladie de Fabry, Maladies génétiques, Maladies lysosomales, Métabolomique, Mucopolysaccharidoses, Prééclampsie, Spectométrie de masse, Thérapie génique.

Intérêts de recherche

Une méthode simple par spectrométrie de masse en tandem pour l'analyse d'un biomarqueur, le globotriaosylcéramide (Gb3) a été développée pour la maladie de Fabry. Notre projet vise des études en métabolomique s'orientant vers la découverte de biomarqueurs au niveau de maladies lysosomales par des techniques d'empreintes et de profils métaboliques par spectrométrie de masse en temps de vol.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2018) Prix Gilles Pigeon. Faculté de médecine et des sciences de la santé. (Prix / Récompense).
  • (2017) Prix mission universitaire et rayonnement Gala du CIUSSS de l'Estrie CHUS (26 octobre 2017). Centre Hospitalier Univ. de Sherbrooke. (Prix / Récompense).
  • (2015) RECMUS, recognition for tutoring students. Université de Sherbrooke. (Prix / Récompense).
  • (2013) Proteomass Scientific Society Award for the Achievements Related to the Study of Newborn Inherited Metabolic Disorder. Proteomass Scientific Society. (Prix / Récompense).
  • (2012) Mérite Estrien. La Tribune et Radio-Canada. (Distinction).
  • (2011) Portrait. Journal de Stanstead. (Distinction).
  • (2010) Autoportrait "La biochimie génétique orientée . Ordre des chimistes. (Distinction).
  • (2010) Émission Campus, Canal Savoir. Télé-Québec. (Distinction).
  • (2009) Portrait de Leader. Université de Sherbrooke. (Distinction).
  • (2009) Reportage : La maladie de Fabry. Découvrir, La Revue de la recherche de l'ACFAS. (Distinction).
  • (2009) « Découverte » Scientifict TV Program. Radio-Canada. (Distinction).
  • (2008) Prix d'Excellence 2008 de l'ADESAQ. L'Association des doyens des études supérieures au Québec. (Distinction).
  • (2008) Prix de la meilleure thèse de doctorat U de S. Récipiendaire du Prix du vice-rectorat à la recherche et vice-rectorat aux études supér. (Distinction).
  • (2007) Prix d'Excellence du CHUS, Catégorie Conseil multi. Centre Hospitalier Universitaire de Sherbrooke. (Distinction).
  • (2005) Prix de l'Exemple. Centre de Réadaptation Estrie. (Distinction).

Financement

Subvention. (Obtenu). Chercheur principal. Batten disease (CLN2) biomarker discovery in urine and plasma using a mass spectrometry metabolomic approach. Biomarin Pharmaceutical Inc. biomarin. 397248 $ (2019-2022).

Subvention. (Obtenu). Collaborateur. Rehaussement de la plateforme technologique pour la médecine génétique préventive. Fondation R. Howard Webster. Fondation R. Howard Webster /Scientific Human Research. 150000 $ (2019-2021).

Subvention. (Obtenu). Chercheur principal. Evaluation of biomarkers for patients receiving Migalastat after switching from enzyme replacement therapy. Amicus Therapeutics (USA). amicus. 404653 $ (2019-2021).

Contrat. (Obtenu). Chercheur principal. An open-label, multinational study of the efficacy and safety of ex vivo lentiviral vector-mediated gene therapy AVR-RD-01 for treatment-naïve subject with classic Fabry disease. Avrobio Inc. Compagnie privée. 304080 $ (2018-2021).

Contrat. (Obtenu). Chercheur principal. Biomarker analysis in the phase III clinical trials of PRX-102 from Protalix. Protalix Ltd. Compagnie privée. 644085 $ (2017-2020).

Contrat. (Obtenu). Chercheur principal. Biomarker Gb3 and lyso-Gb3 analysis. Sigilon Therapeutics. Mouse Research Study. 89362 $ (2018-2019).

Subvention. (Obtenu). Chercheur principal. Metabolomic studies for discovery of novel Gaucher disease biomarkers, and development and validation of methods in urine and plasma, (excluding type 2 and type 3 Gaucher disease). Shire Human Genetic Therapies. IIR. 432835 $ (2016-2019).

Subvention. (Obtenu). Chercheur principal. Development and Validation of a Tandem Mass Spectrometry Methodology for the Analysis of Dermatan Sulfate and Heparan Sulfate in MPS II Mice Tissues. Shire Human Genetic Therapies. IIR. 302569 $ (2017-2019).

Contrat. (Obtenu). Chercheur principal. Biomarker Gb3 and lyso-Gb3 from plasma and tissues will be analyzed. Moderna Therapeutics. Compagnie privée. 299541 $ (2016-2019).

Subvention. (Obtenu). Co-demandeur. Towards individual personalized management of ERT treated female Fabry disease Danish patients who are part of a nationwide long-term clinical registry in regards to plasma and urine novel glycosphingolipid biomarkers and the genotype. Shire Human Genetic Therapies. IIR. 372940 $ (2016-2019).

Subvention. (Obtenu). Collaborateur. Rehaussement de la plateforme technologique pour la médecine génétique préventive et l'ensemble des nouveaux-nés du Québec. Fondation J.A. de Sève. Scientific Human Research. 180000 $ (2018).

Subvention. (Obtenu). Demandeur principal. Biomarker evaluation for Fabry Disease SRT study. Genzyme Corp. Biomarker evaluation for SRT study for Fabry Disease. 28056 $ (2016-2017).

Subvention. (Obtenu). Demandeur principal. Programme de développement professionnel continu portant sur les manifestations cliniques et biologiques de la maladie de Gaucher. Shire. Formation continue. 71708 $ (2016-2017).

Contrat. (Obtenu). Demandeur principal. Development and validation of a Tandem Mass Spectrometry methodology for the Analysis of Keratan Sulfate Disaccharides in Urine Samples collected on Filter paper for patients with Mucopolysaccharidosis type IVA.. Biomarin Pharmaceutical Inc. IIR. 130000 $ (2016-2017).

Subvention. (Obtenu). Chercheur principal. Waters Limited MS Research group. Waters Limited. Partenariat scientifique de développement en spectrométrie de masse. 16900 $ (2016).

Subvention. (Obtenu). Co-demandeur. Identification of Novel Teratogens and Foeto-toxic Drugs: Epidemiology, Pharmacology, Tocxicity, and Mechcnisms of Action. RQRM, Université de Montréal/ Université de Sherbrooke. 85000 $ (2012-2013).

Subvention. (Obtenu). Co-demandeur. High-risk screening for Fabry disease in males and females with chronic kidney disease.. Genzyme Canada. 14800 $ (2011-2012).

Subvention. (Obtenu). Co-chercheur. L'hémoglobine foetale glyquée: un marqueur de la programmation foetale?. Fondation des étoiles (La) (Qc). 10000 $ (2011-2012).

Bourse de recherche. (Obtenu). Demandeur principal. Évaluation du lyso-ene-Gb3 chez les enfants atteints de la maladie de Fabry. Fondation des étoiles (La) (Qc). 10000 $ (2011-2012).

Bourse de recherche. (Obtenu). Demandeur principal. Études biochimiques et métabolomiques des biomarqueurs du diabète gestationnel chez le foetus et la mère.. Fondation des étoiles (La) (Qc). 20000 $ (2009-2010).

Subvention. (Obtenu). Demandeur principal. Évaluation d'un nouveau biomarqueur pour la maladie de Fabry. Fondation de la Recherche Sur les Maladies Infantiles (Qc). 20000 $ (2008).

Publications

Articles de revue

  • Limgala RP, Jennelle T, Plassmeyer M, Boutin M, Lavoie P, Abaoui M, Auray-Blais C, Nedd K, Alpan O, Goker-Alpan O. (2019). Altered immune phenotypesin subjects with Fabry disease and responses to switching from agalsidase alfato agalsidase beta. Am J Transl Res., 11 (3), 1683-1696. (Article publié).
  • Levtova A, Waters PJ, Buhas D, Lévesque S, Auray-Blais C, Clarke JTR, Laframboise R, Maranda B, Mitchell GA, Brunel-Guitton C, Braverman NE. (2019). Combined malonic and methylmalonic aciduria due to ACSF3 mutations: Benign clinical course in an unselected cohort.2019 Jan;42(1):107-116. J Inherit Metab Dis, 42((1)), 107-116. (Article publié).
  • Menkovic I, Lavoie P, Boutin M, Auray-Blais C. (2019). Distribution of heparansulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissuespre- and post-enzyme-replacement therapy determined by UPLC-MS/MS. Bioanalysis, 11(8), 727-740. (Article publié).
  • Medin JA, Khan A, Huang J, Barber D, Rupar CA, Auray-Blais C, Fraser G, Fowler DH, Keating A, West ML, Foley R. (2019). FACTs Fabry gene therapy clinical trial: Two-year data. Molecular Genetics and Metabolism, 126((2)), s99. (Article publié).
  • Auray-Blais C, Lavoie P, Abaoui M, Côté AM, Boutin M, Akbari A, Levin A, Mac-Way F, Tr Clarke J. (2019). High-Risk Screening for Fabry Disease in a Canadian Cohort of Chronic Kidney Disease Patients. Clin Chim Acta, 91(2), 284-293. DOI. (Article publié).
  • Lenders M, Stappers F, Niemietz C, Schmitz B, Boutin M, Ballmaier PJ, Zibert A, Schmidt H, Brand SM, Auray-Blais C, Brand E. (2019). Mutation-specificFabry disease patient-derived cell model to evaluate the amenability tochaperone therapy. J Med Genet, 56((8)), 548-556. (Article publié).
  • Menkovic I, Marchand AS, Boutin M, Auray-Blais. (2019). Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. Diagnostics, 195(4), 9. DOI. (Article publié).
  • Martineau T, Boutin M, Côté AM, Maranda B, Bichet DG, Auray-Blais C. (2019). Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clin Chim Acta, 495, 67-75. DOI. (Article publié).
  • Alharbi FJ, Baig S, Rambhatla SB, Vijapurapu R, Auray-Blais C, Boutin M, Steeds R, Wheeldon N, Dawson C, Geberhiwot T. (2019). The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease. Clin Chim Acta, 54(4), 307-314. DOI. (Article publié).
  • Toupin A, Lavoie P, Arthus MF, Abaoui M, Boutin M, Fortier C, Ménard C, Bichet DG, Auray-Blais C. (2018). Analysis of globotriaosylceramide (Gb3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. Anal Chim Acta, 1015, 35-49. DOI. (Article publié).
  • Pirault M, Pettazonni M, Lavoie P, Ruet S, Pagan C, Cheilland D, Latour P, Vianey Saban C, Auray-Blais C, Froissart R. (2018). Contribution of mass spectrometry to the diagnosis of lysosomal storage disorders,. Journal of Inherited Metabolic Disease, 41(3), 457-477. (Article publié).
  • Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, Auray-Blais C, West ML, Oudit GY. (2018). Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. 2018 Nov 6;7(21):e009098. J Am Heart Assoc., 7((21)), e009098. (Article publié).
  • Alharbi FJ, Baig S, Auray-Blais C, Boutin M, Ward DG, Wheeldon N, Steed R, Dawson C, Hughes D, Geberhiwot T. (2018). Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. J Inherit Metab Dis. 2018 ., 41(2), 239-247. DOI. (Article publié).
  • Toupin A, Lavoie P, Arthus MF, Abaoui M, Boutin M, Fortier C, Ménard C, Bichet DG, Auray-Blais C. (2018). Mass Spectrometry Analysis of Globotriaosylceramide (Gb3) Isoforms/Analogs in Unfractionated Leukocytes, B Lymphocytes and Monocytes from Fabry Patients,. Analytica Chimica Acta, (1015), 35-49. (Article publié).
  • Auray-Blais Christiane, Collerette-Tremblay Jasmin, Lavoie Pamela. (2018). UPLC-MS/MS analysis of keratan sulfate from urine samples collected on filter paper for monitoring and follow-up of Morquio A patients. Bioanalysis, BIO-2018-0064.R2, 1181-1192. (Article publié).
  • Christiane Auray-Blais, LL.M., Ph.D.a*; Pamela Lavoie, M.Sc a*; Michel Boutin, Ph.D.a; Aimé Ntwari, Ph.D.a; Huang Chun-Kai, M.Sc.c; Hsu Ting-Rong, M.D.b,c; Dau-Ming Niu, M.D., Ph.D.b,c*. (2017). Biomarkers Associated with Clinical Manifestations in Fabry Disease Patients with a Late-Onset Cardiac Variant Mutation. Clin Chim Acta., 466, 185-193. (Article publié).
  • Waters PJ, Kitzler TM, Feigenbaum A, Geraghty MT, Al-Dirbashi O, Bherer P, Auray-Blais C, Gravel S, McIntosh N, Siriwardena K, Trakadis Y, Brunel-Guitton C, Al-Hertani W. (2017). Glutaric aciduria type 3:three unrelated Canadian cases, with different routes of ascertainment. JIMD Reports, (2 août), (Article publié).
  • Auray-Blais, C., Lavoie, P., Boutin, M. and Abaoui, M. (2017). High-risk screening for Fabry disease: Analysis by tandem mass spectrometry of globotriaosylceramide (Gb3) in urine collected on filter paper. Curr. Protoc. Hum. Genet., 93 17.26..26.12., 1-17. (Article publié).
  • Huang J, Khan A, A BC, Barber DL, López-Vásquez L, Boutin M, Rothe M, Rip JW, Abaoui M, Nagree MS, Dworski S, Schambach A, Keating A, West M, Turner P, Sirrs S, Rupar CA, Auray-Blais C, Foley R, Medin JA. (2017). Lentivector Iterations and Pre-clinical Scale-up/Toxicity testing: Targeting Patient Mobilized CD34+ Hematopoietic Cells for Correction of Fabry Disease. Molecular Therapy-Methods & Clinical Development, 5, 241-258. (Article publié).
  • Boutin M, Menkovic I, Martineau T, Vaillancourt-Lavigueur V, Toupin A, Auray-Blais C. (2017). Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. Anal Chem. Dec 19 doi: 10.1021/acs.analchem.7b03609. Epub 2017 Nov 27., 89(24), 13382-13390. (Article publié).
  • Nelson MP, Boutin M, Tse TE, Lu H, Haley ED, Ouyang X, Zhang J, Auray-Blais C, Shacka JJ. (2017). The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiol Dis. doi: 10.1016/j.nbd.2017.11.006. Epub 2017 Dec 2., 110(Feb;110), 68-81. (Article publié).
  • Lévesque S, Auray-Blais C, Gravel E, Boutin M, Dempsey-Nunez L, Jacques PE, Chenier S, Larue S, Rioux MF, Al-Hertani W, Nadeau A, Mathieu J, Maranda B, Désilets V, Waters PJ, Keutzer J, Austin S, Kishnani P. (2016). Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. Orphanet J Rare Dis., 11(1), 8. (Article publié).
  • Kamani MA, Provencal P, Boutin M, Pacienza N, Fan X, Novak A, Huang TC, Binnington B, Au BC, Auray-Blais C, Lingwood CA, Medin JA. (2016). Differential Acyl Chain Storage of Multiple Glycosphingolipids in Fabry Mice. Future Science OA, 2(4), (Article publié).
  • Auray-Blais C, Lavoie P, Maranda B, Boutin M. (2016). Evaluation of keratan sulfate disaccharides in patients affected with Morquio A syndrome (Mucopolysaccharidosis type IVA) using UPLC-MS/MS. Bioanalysis, 8(3), 179-191. (Article publié).
  • Lavoie P, Boutin M, Abaoui M, Auray-Blais C. (2016). Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry. Curr Protoc Hum Genet., 90:17.22..22.12, 1-17. (Article publié).
  • Mustafa A Kamani, Philippe Provençal, Michel Boutin, Natalia Pacienza, Xin Fan, Anton Novak, Tonny C Huang, Beth Binnington, Bryan C Au, Christiane Auray-Blais, Clifford A Lingwood, Jeffrey A Medin. (2016). Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. Future Sci OA. Oct 13;2(4):FSO147., 2(4), 147. (Article publié).
  • Abaoui M, Michel Boutin M, Lavoie P, Auray-Blais C,. (2016). High-Risk Screening of Fabry Disease : Analysis of Fifteen Urinary Methylated and Non-Methylated Gb3 Isoforms using Tandem Mass Spectrometry. Curr Protoc Hum Genet, Oct 11;91:, 17.24.1-17.24.11. (Article publié).
  • Battista MC, Boutin M, Venne P, Blais L, Bérard A, Lacroix M, Patenaude J, Guillemette L, Cossette C, Hivert MF, Auray-Blais C. (2016). Maternal inhaled fluticasone propionate intake detected in neonatal cord blood. Bioanalysis, (Jun 28), (Article publié).
  • Provençal P, Boutin M, Dworski S, Au B, Medin JA, Auray-Blais C. (2016). Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis, 8(Sep;8(17)), 1793-807. (Article publié).
  • Spacil Z, Kumar AB, Auray-Blais C, Stark S, Suhr TR, Scott CR, Turecek F, Gelb MH. (2016). Sulfatide Analysis by Mass Spectrometry for Screening of Metachromatic Leukodystrophy in Dried Blood and Urine Samples. Clinical Chemistry, 62, 279-86. (Article publié).
  • Abaoui M, Boutin M, Lavoie P, Auray-Blais C. (2016). Tandem Mass Spectrometry Multiplex Analysis of Methylated and Non-Methylated Urinary Gb3 Isoforms in Fabry Disease Patients. Clin Chim Acta., 452, 191-198. (Article publié).
  • Boutin M, Lavoie P, Abaoui M, Auray-Blais C. (2016). Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients. Curr Protoc Hum Genet., 90:17.23, 1-9. (Article publié).
  • Boutin M, Sun Y, Shacka JJ,, Auray-Blais C. (2016). Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson disease. Anal Chem., 88(3), 1856-63. (Article publié).
  • Auray-Blais C, Lavoie P, Tomatsu S, Valayannopoulos V, Mitchell JJ, Raiman J, Beaudoin M, Maranda B, Clarke JTR. (2016). UPLC-MS/MS Detection of Disaccharides Derived from Glycosaminoglycans as Biomarkers of Mucopolysaccharidoses. Anal Chim Acta, 936(Sept14;936), 139-48. (Article publié).
  • Rigden M, Pelletier G, Poon R, Zhu Jiping, Auray-Blais C, Gagnon René, Kubwabo C, Kosarac I, Lalonde K, Cakmak S, Xiao B, Leingartner K, Ku KL, Bose R, Jiao J,. (2015). Assessment of Urinary Metabolite Excretion Following Rat Acute Exposure to Perfluoroocta. Archives of Environmental Contamination and Toxicology, 68(1), 148-158. (Article publié).
  • Boutin M., Auray-Blais C. (2015). Metabolomic Discovery of Novel Urinary Galabiosylceramide Analogs as Fabry Disease Biomarkers. J. Amer. Soc. Mass Spectrom., 26(3), 499-510. (Article publié).
  • Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JTR, Bichet DG, Warnock DG, Echevarria L, Lavoie P. (2015). Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta, 438C, 195-204. (Article publié).
  • Ferreira S, Auray-Blais C, Boutin M, Lavoie P, Nunes JP, Martins E, Garman S, Oliveira JP. (2015). Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clin. Chim. Acta, 447, 96-104. (Article publié).
  • FO Dupont, MF Hivert, C Allard, J Menard, P Perron, L Bouchard, J Robitaille, JC Pasquier, C Auray-Blais, JL Ardilouze. (2014). Glycation of fetal hemoglobin reflects hyperglycemia exposure in utero. Diabetes Care, 37(10), 2830-2833. (Article publié).
  • Auray-Blais C, Maranda B, Lavoie P. (2014). High-throughput tandem mass spectrometry multiplex analysis for newborn urinary screening of creatine synthesis and transport disorders, Triple H syndrome and OTC deficiency. Clin Chim Acta, 436C(Sept25;436), 249-255. (Article publié).
  • Boutin M, Auray-Blais C. (2014). Multiplex Tandem Mass Spectrometry Analysis of Novel Plasma Lyso-Gb3-Related Analogues in Fabry Disease. Anal.Chem., 86(7), 3476-3483. (Article publié).
  • Sirrs SM1, Bichet DG2, Casey R3, Clarke JT4, Lemoine K5, Doucette S6, West ML7; CFDI investigators. Chan A, Dyack S, Greenberg C, MacKenzie J, Maranda B, Mhanni A, Morel C, Murphy S, Prasad C, Raiman J, Turner L, Moore D, Auray- Blais C, Sinasac D, Chodirker B, Willa A. (2014). Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab., 111(4), 499-506. (Article publié).
  • Dupont FO, Gagnon R, Boutin M, Auray-Blais C. (2013). A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs as Fabry Disease Biomarkers. Curr Med Chem., 20(2), 280-288. (Article publié).
  • Manwaring V, Boutin M, Auray-Blais C. (2013). A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients. Anal Chem, 85(19), 9039-9048. (Article publié).
  • Lavoie P, Boutin M, Auray-Blais C. (2013). Multiplex Analysis of Novel Urinary Lyso-Gb(3)-Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry. Anal Chem., 85(3), 1743-1752. (Article publié).
  • Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R. (2010). How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clin Chim Acta, 411((23-24)), 1906-1914.
  • Schiffmann R, Waldek S, Benigni A, Auray-Blais C. (2009). Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol, 5(2),
  • Auray-Blais C, Giguère R, Lemieux B. (2003). Newborn urine screening programme in the province of Quebec: an update of 30 years' experience. J Inherit Metab Dis, 26(4), 393-402.

Chapitres de livre

  • Lavoie P, Auray-Blais C. (2018). Depolymerisation of GAGs by Methanolysis and Analysis by Tandem Mass Spectrometry, Chapter 30. Nova Science Publishers, Inc. Mucopolysaccharidoses Update (2 Volume Set) (ISBN: 978-1-53613-986-0). États-Unis : Shunji Tomatsu, Chief-Editor. (Article publié).
  • Auray-Blais, C. (2015). Les soins du bébé, Dépistage des maladies métaboliques héréditaires. INSPQ Mieux vivre avec notre enfant de la grossesse à 2 ans, ISBN : 978-2-550-60380-1 Canada : INSPQ. (Article publié).
  • Auray-Blais, C., Giguère, R., Girard, J.G., Lemieux, B. (1999). Le Programme de dépistage urinaire des nouveau-nés du Québec et la collaboration des parents. Marcel J. Mélançon et Richard Gagné Diagnostic et dépistage génétiques. Aspects cliniques, juridiques, éthiques et sociaux. (44-48). Canada : Les Presses de l'Université Laval. (Article publié).

Autres contributions

Cours enseignés

  • Cytogénétique et génétique biochimique. GNT 630. (2016-08-30). Université de Sherbrooke. Canada.
  • Cours Biomolécules: Caractérisation et applications. BCM 502. (2013-09-16). Université de Sherbrooke. Canada.
  • Biochimie clinique. BCM 605. (2013-01-07). Université de Sherbrooke. Canada.
  • Cytogénétique humaine et médicale. GNT 616. (2013-01-07). Université de Sherbrooke. Canada.
  • Spectrométrie de masse et applications en santé. RBL 740. (2013-01-07). Université de Sherbrooke. Canada.
  • Génétique humaine et médicale. GNT 516. (2012-09-10). Université de Sherbrooke. Canada.

Gestion d'évènements

  • co-présidente et membre du comité organisateur. (2019). 7e Encan des vins de Sherbrooke, événement caritatif.
  • Co-organizer and Chairman. (2018). 1st Canadian Symposium on Lysosomal Diseases. (Conférence).
  • présidente et membre du comité scientifique organisateur. 5e Symposium sur la spectrométrie de masse. (Conférence).
  • présidente et membre du comité scientifique organisateur. 6e Symposium sur la spectrométrie de masse. (Conférence).
  • présidente et membre du comité scientifique organisateur. 7e Symposium sur la spectrométrie de masse. (Conférence).
  • présidente et membre du comité scientifique organisateur. 8e Symposium sur la spectrométrie de masse. (Conférence).

Activités de collaboration internationale

  • Directrice scientifique. (2019). Waters Center of Innovation, premier centre canadien Waters.
  • Membre du comité Fabry Disease Biomarker Working Group. (2009). France. Élaborer et planifier un projet de recherche international sur les biomarqueurs de la maladie de Fabry en collaboration avec la compagnie Genzyme, division de SANOFI.

Présentations

  • (2019). 146. Is Plasma Lyso-Gb3 Sufficient as the Only Sphingolipid Biomarker. 5th Meeting of the Nordic Fabry Expert Group, October 1st. Hveragerdi,, Islande.
  • (2019). 147. Lyso-Gb3 and Analogues: CFDI and FACTs Longitudinal Study. CFDI National Registry Annual Meeting. Toronto, Canada.
  • (2019). 150. UPLC-MS/MS Detection of Biomarkers of Mucopolysaccharidoses,. GRIDS 2019 – Neurological Outcomes in Lysosomal Disorders. Fairfax, États-Unis.
  • (2019). A Metabolomic Approach for Biomarker Discovery and Precision Medicine,. 1st Eastern Canada MS Conference,. Sherbrooke, Canada.
  • (2019). A Metabolomic Approach for Biomarker Discovery and Precision Medicine,. 1st Eastern Canada MS Conference. Lennoxville, Canada.
  • (2019). Biomarker Discovery and Translational Research Leading to Clinical Utility: Experimental Approaches and Pitfalls. MSACL EU 2019. Salzburg, Australie.
  • Michel Boutin. (2019). Biomarker Discovery and Translational Research Leading to Clinical Utility: Experimental Approaches and Pitfalls. MSACL EU 2019. Salzburg, Autriche.
  • (2019). Correlations Between Podocyturia and Lyso-Gb3 Analogues in Fabry Disease. European Symposium on LSDs (ESLSD), Guided Poster Tour Presentation, November 15, 2019. Madride, Espagne.
  • (2019). Correlations Between Podocyturia and Lyso-Gb3 Analogues in Fabry Disease,. European Symposium on LSDs (ESLSD. Madrid, Espagne.
  • (2019). Is Plasma Lyso-Gb3 Sufficient as the Only Sphingolipid Biomarker?. 5th Meeting of the Nordic Fabry Expert Group, October 1st, 2019. Hveragerdi, Islande.
  • (2019). Lyso-Gb3 and Analogues: CFDI and FACTs Longitudinal Study. CFDI National Registry Annual Meeting, October 4th, 2019. Ontario, Canada.
  • (2019). Lyso-Gb3 and Analogues in Fabry Disease,. Sanofi-Genzyme Advisory Board. Boston, États-Unis.
  • (2019). Lyso-Gb3 and Analogues in Fabry Disease,. Sanofi-Genzyme Advisory Board,. Boston, États-Unis.
  • (2019). Lyso-Gb3 and Analogues in Late-Onset Attenuated Variants, ,. 6th Update on Fabry Disease, Biomarkers, Progression and Treatment Opportunities. Prague, Tchèque, République.
  • (2019). Newborn Urine Screening for Mucopolysaccharidoses Using a Tandem Mass Spectrometry Approach. Takeda Invitation,. Toronto, Canada.
  • (2019). Novel Biomarkers for Podocyturia Evaluation in Fabry Disease. Fabry Connections (Amicus). London, Royaume-Uni.
  • (2019). Novel Biomarkers for Podocyturia Evaluation in Fabry Disease. Fabry Connections (Amicus) October 26, 2019. Londres, Ukraine.
  • (2019). Podocyturia Evaluation in Fabry Disease Using a Mass Spectrometry Approach,. RARD Meeting. Bogota, Colombie.
  • (2019). Podocyturia Evaluation in Women with Preeclampsia and Fabry disease Patients Using a Tandem Mass Spectrometry Approach. MSACL EU 2019. Salzburg, Autriche.
  • (2019). Podocyturia Evaluation in Women with Preeclampsia and Fabry disease Patients Using a Tandem Mass Spectrometry Approach. MSACL EU 2019. Salzburg, Autriche.
  • (2019). The Significance of Mass Spectrometry for Translational Research in Precision Medicine,. Waters User’s Meeting. Atlanta, États-Unis.
  • (2019). UPLC-MS/MS Detection of Biomarkers of Mucopolysaccharidoses. GRIDS 2019 – Neurological Outcomes in Lysosomal Disorders, November 25, 2019. Fairfax, États-Unis.
  • (2018). A Technological Upgrade for Newborn Mass Urine Screening in the Province of Quebec: From TLC to MS/MS. SSIEM Symposium, 5 septembre 2018. Athens, Grèce.
  • (2018). Biomarqueurs pour la maladie de Fabry et recherche translationnelle: du laboratoire jusqu'au suivi des patients. Souper-conférence organisé par Genzyme - Sanofi. Montréal, Canada.
  • (2018). Liquid Chromatography-Tandem Mass Sectrometry Quantitative Biomarker Evaluation of Vitreous Fluid from a Gaucher Disease Type 3 Patient with Severe Ocular Involvement,. ESLSD - Shire Poster et possibilité de présentation orale 25 octobre 2018. Vienne, Autriche.
  • (2018). Role of Lyso-Gb3 and Analogues as Biological Markers in Fabry Disease,. Fabry Connections - Amicus October 20 2018. Madrid, Espagne.
  • (2018). The Importance of Biomarker Discovery in Precision Medicine. BIT's 9th World Gene Convention 2018 13 novembre 2018. Singapour.
  • (2018). The Role of Chromatography in the Separation of Glucosylceramide Isoforms from their Isobaric Galactosylceramide Counterparts in the Era of Precision Medicine. MSACL 2018 EU, Salzburg Austria, September 13, 2018. Salzburg, Australie.
  • (2018). UPLC-MS/MS Analysis of Keratan Sulfate Using Urine Samples COllected on Filter Paper, uGAG MS/MS Based Medthod Scienctific Workshop. Pour BiomMarin - Pharmaceutical September 3, 2018. Athens, Grèce.
  • (2017). Biomarkers in Translational Research: From Discovery to Clinical Applications,. Waters ASMS Users Meeting June 3rd 2017. Indianapolis, IN, États-Unis.
  • (2017). Biomarqueurs pour la maladie de Fabry: dépistage, diagnostic et suivi des patients,. Souper-conférence. Sherbrooke, QC, Canada.
  • (2017). Emerging Biomarkers in LSDs. 1st Shire R&D Research Series “Shaping What’s Next in LSDs – Hot Topics” July 8, 2017. Londres, Royaume-Uni.
  • (2017). Fabry Disease Biomarkers,. Principal Investigators Meeting, Protalix Biotherapeutics Inc. New York, March 10 2017. New York, NY, États-Unis.
  • (2017). High-Risk Screening for Fabry Disease: What Can Easily Be Done for Early Detection. Fabry MasterClass Madrid Spain, May 6 2017. Madrid, Espagne.
  • (2017). Les mucopolysaccharidoses: physiopathologie et nouveaux tests de dépistage par spectrométrie de masse. Souper-conférence Sherbrooke, QC, February 22 2017. Sherbrooke, Canada.
  • (2017). Lyso-Gb3 and Analogues in Cardiac Variant Mutations. 5th Update on Fabry Nephropathy Mexico City, Mexico, April 26 2017. Mexico, Mexique.
  • (2017). Mass Urine Screening for Inherited Metabolic Disorders Using a Reliable and Inexpensive Thin Layer Chromatography Methodology, Xth ISNS-Asia Pacific. Regional Meeting APRM 2017. Oulan Bator, Mongolie.
  • (2017). Next Generation Sequencing: An Emerging Clinical Tool. Canadian Neurological Sciences Federation (CNSF), 52nd Annual Congress, Victoria, BC - June 20th 2017. Victoria, Canada.
  • (2017). What can newly discovered Fabry disease biomarkers reveal about disease severity?. RARD, 2017 Moscow, May 20 2017. Moscow, Russie, Fédération de.
  • (2016). Advances in Patient Diagnosis. MPS MasterClass Advanced. Barcelona, Espagne.
  • (2016). A reliable multiplex mass spectrometry analysis of glycosaminoglycans for mucopolysaccharidoses. Sept. 7 2016,. SSIEM Annual Symposium. Rome, Italie.
  • (2016). Biomarkers for Fabry Disease Patients with a Late-Onset Cardiac Variant Mutation,. Fabry Conference of Chinese Medical Association Meeting. Taipei, Taïwan, Province de Chine.
  • (2016). Découverte de biomarqueurs pour les maladies lysosomales utilisant une approche métabolomique,. Groupe de Ste-Justine, Souper-conférence Montréal, QC, 12 décembre 2016. Montréal, QC, Canada.
  • (2016). Mass Spectrometry Applications: From Biomarker Discovery to Detection of Patients with Fabry Disease Having a Late-Onset Cardiac Mutation. MSACL 2016 EU Congress Chairman and Lecturer. Salzburg, Autriche.
  • (2016). Mass Spectrometry Applications: From Biomarker Discovery to Detection of Patients with Fabry Disease Having a Late-Onset Cardiac Mutation Chairman and lecturer, Sept. 14 2016. MSACL 2016 EU Congress. Salzburg, Autriche.
  • (2016). Mass Spectrometry Biomarker Analysis for the Identification, Monitoring and Follow-up of Patients. Garrod Annual Symposium. Halifax, NS, Canada.
  • (2016). Principles of Metabolomics for Biomarker Discovery and Translational Research. Garrod Lunch Symposium. Halifax, NS, Canada.
  • (2016). Qu'elle place pour le lyso-Gb3 et ses analogues dans le diagnostic et le suivi de la maladie de Fabry. Symposium Amicus Therapeutics. Deauville, France.
  • (2016). Recent Advances in Biomarker Discovery for Fabry Disease: Detection, Diagnosis, and Monitoring Patients. Fabry Forum 2016. Tokyo, Japon.
  • (2016). Recent Advances in Biomarker Discovery for Fabry Disease: Detection, Diagnosis, and Monitoring Patients. Meet the Specialist. Yokohama, Japon.
  • (2015). La mucopolysaccharidose: symptômes et diagnostic. Clinique pédiatrique de Ste-Foy. Ste-Foy, QC, Canada.
  • (2015). La mucopolysaccharidose: symptômes et diagnostic. Souper-conférence aux pédiatres. Lévis, QC, Canada.
  • (2015). Mass Spectrometry approaches for translational research: from biomarker discovery to clinical application. International Summit on Current Trends in Mass Spectrometry. New Orleans, LA, États-Unis.
  • (2015). Metabolomic Approaches to Understanding Biomarkers in LSDs. European symposium on LSDs. Barcelone, Espagne.
  • (2015). Novel biomarkers for Fabry disease patients. Fabry Masterclass VII. Warsaw, Pologne.
  • (2015). Understanding biomarkers in LSDs - A metabolomic approach. Gaucher Expert Summit. Amsterdam, Pays-Bas.
  • (2015). Urinary Biomarkers in Translational Research: From Discovery to Clinical Applications. Urinomics and Nephromics 2015 meeting. Caparica, Portugal.
  • (2014). Analysis of Glycosaminoglycans Using Tandem Mass Spectrometry and uKS LC-MS/MS Validation. BioMarin Steering Committe. Nashville, TN, États-Unis.
  • (2014). Biomarker Discovery and analysis for lysosomal storage disorders using mass spectrometry. Waters Seminar (Calgary Children’s Hospital/University of Calgary). Calgary, AB, Canada.
  • (2014). Biomarker discovery to clinical applications: Down to basics!. Canadian Society for Mass Spectrometry, Lake Louise Tandem Mass Spectrometry Workshop. Lake Louise, AB, Canada.
  • (2014). Biomarkers for Fabry disease: More is Better. 1st Meeting of Nordic Fabry Expert Group Copenhagen, Denmark, November 28 2014. Copenhague, Danemark.
  • (2014). Biomarkers for Fabry disease Patients with Cardiac Variant Mutations. CFDI 2014 Annual Meeting. Vancouver, BC, Canada.
  • (2014). Discovery of Biomarkers for Fabry patients with cardiac variant mutations. Waters Seminar (Stollery Hospital). Edmonton, MB, Canada.
  • (2014). Découverte et analyse de nouveaux biomarqueurs pour la maladie de Fabry utilisant la spectrométrie de masse. Grand Rounds de Néphrologie. Québec, QC, Canada.
  • (2014). Fabry Biomarkers: from discovery to clinical applications. Langdon Hall Annual Meeting. Cambridge, ON, Canada.
  • (2014). From Benchtop to Bedside: the Importance of Efficient Biomarkers for Identification and Follow-up of Rare Disorders. Genetic, Rare and Immune Disorders Symposium; Rare is common – A Cross-Section for the Practitioner. Fairfax, VA, États-Unis.
  • (2014). Health Care System in Canada and Clinical Research Activities at CRC-CHUS. Medical Grand Rounds in the Pediatric Department, Taipei Veterans General Hospital. Taipei, Taïwan, Province de Chine.
  • (2014). Lyso-Gb3 Analogue Analysis for Fabry disease. Neonatal Screening Center of the Chinese Foundation of Health. Taipei, Taïwan, Province de Chine.
  • (2014). Mass Spectrometry Analysis of Novel Lyso-Gb3 Analogues. 3rd European Fabry Expert Lounge. Rome, Italie.
  • (2014). Mass Spectrometry Approaches for Biomarker Discovery and Analysis in Fabry disease. National Yang-Ming University, Microbiology and Immunology, the School of Life Sciences. Taipei, Taïwan, Province de Chine.
  • (2014). Mass or High-Risk Screening of Creatine Synthesis and Transport Disorders, Triple H Syndrome and OTC Deficiency Using a Multiplex Tandem Mass Spectrometry Methodology. Garrod 2014 Annual Meeting. Ottawa, Canada.
  • (2014). Mass spectrometry detection of novel biomarkers for Fabry patients with cardiac variant mutations. Fabry Expert Summit. Ottawa, ON, Canada.
  • (2014). Quantitative UPLC-MS/MS Multiplex Urinary Analysis of Glycosaminoglycans for MPS Patients. 13th International Symposium on MPSs and Related Diseases. Bahia, Brésil.
  • (2014). Rapport 2014, CRC-CHUS. Assemblée annuelle, Fondation des Étoiles. Montréal, QC, Canada.
  • (2014). The Provincial Mass Urinary Screening Program for Inherited Metabolic Disorders in the Province of Quebec. Genetic Counseling Center, Taipei Veterans General Hospital. Taipei, Taïwan, Province de Chine.
  • (2014). Validation of the Martell uKs Method Using a UPLC-MS/MS System. BioMarin Steering Committee. Bahia, Brésil.
  • (2013). A Urinary Metabolomic Approach for Fabry Disease Patients Leads to Novel Biomarker Detection and their Relative Quantification. Urinomics 2013, 1st International Conference on urine analysis. Caparica, Portugal.
  • (2013). Discovery of Novel Biomarkers for Fabry Patients with Cardiac Variant Mutations. MolMed 2013 Présidente de session et conférencière invitée. Haikou, Chine.
  • (2013). Discovery of Novel Biomarkers for Fabry disease Using a Mass Spectrometry Metabolomic Approach. 9th Metabolomics Meeting 2013. Glasgow, Scotland, Royaume-Uni.
  • (2013). Découverte de biomarqueurs par la métabolomique. Conférence dédiée. Sherbrooke, QC, Canada.
  • (2013). Fabry Outcome. Biomarkers,LSD Club Meeting. Montréal, QC, Canada.
  • (2013). Gene Therapy for Fabry Disease Patients: The Importance of Efficient Biomarker Monitoring. World 2013 LDN Meeting. Orlando, FL, États-Unis.
  • (2013). Lyso-Gb3 Analogues. Biomarkers, Progression and Treatment Opportunities, Hong Kong 4-5 juin 2013. Hong Kong.
  • (2013). L’utilisation de la spectrométrie de masse: de la métabolomique à l’analyse de biomarqueurs pour la clinique. Journée scientifique JMM, édition 2013, Département d’obstétrique-gynécologie, FMSS, Université de Sherbrooke. Sherbrooke, Canada.
  • (2013). Mass spectrometry: Research and clinical applications. Waters Canada Annual Meeting. Montréal, QC, Canada.
  • (2013). Mass spectrometry approach for novel Fabry disease biomarker detection. 4th International Conference and Exhibition on Analytical & Bioanalytical Techniques. Las Vegas, NV, États-Unis.
  • (2013). Newborn Mass Urine Screening Program for Inherited Metabolic Disorders in the Province of Quebec: a Dynamic Process. 1st International Conference on urine analysis. Caparica, Portugal.
  • (2013). Novel biomarkers for Fabry disease detected by a mass spectrometry metabolomic approach,. ICIEM 2013. Barcelone, Espagne.
  • (2013). Recent Advances in Biomarker Discovery for Fabry Disease. Nephrology Lunch Rounds, St-Paul’s Hospital. Vancouver, BC, Canada.
  • (2013). Recent Advances in Science and Biochemistry. Fabry MasterClass, Mapping the Milestones in Fabry Disease. Madrid, Espagne.
  • (2013). Spectrométrie de masse: Applications en clinique et en recherche. Activité du Thème porteur – Vieillissement, FMSS, Université de Sherbrooke. Sherbrooke, QC, Canada.
  • (2010). Biomarker Research in Medicine by Mass Spectrometry. Jülich Institute Invitation. Julich, Allemagne.
  • (2010). Biomarkers for lysosomal storage disorders using mass spectrometry, Metabolic Disease Biomarkers and Healthcare. 1st Annual Tetra Congress of MolMed 2010. Shangai, Chine.
  • (2010). Gb3, lyso-Gb3 and metabolomic studies using mass spectrometry: how to improve monitoring of Fabry disease patients. 3rd Annual Protein and Peptide Conference. Beijing, Chine.
  • (2010). How Useful is Urinary Lyso-Gb3 As A Biomarker for Fabry Disease?. Lysosomal Disease Network 6th Annual World Symposium 2010. Miami, États-Unis.
  • (2010). Mass Spectrometry Platform. Health Canada Invitation. Ottawa, Canada.
  • (2010). The Use of Urine Gb3 as a Biomarker in Fabry Disease, Fabry disease:. Investigator Research Meeting. Londres, Royaume-Uni.
  • (2010). Urinary lyso-Gb3: Is it a useful biomarker for Fabry disease?. Invitation scientifique. Québec, Canada.
  • (2010). Urine Gb3 and CFDI Fabry patients. CFDI Annual Meeting. Québec, Canada.
  • (2010). Urine lyso-Gb3 and correlations with Gb3 and other parameters. Biomarker Working Group. Munich, Allemagne.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.